CITI Training Requirements
Conflict of Interest Management
Content
Upstate Active Clinical Trials
Study Title:
(CA180372) A Phase II Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaWhat is the purpose of the study?
Treatment study to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemiaUpstate Institutional Review Board (IRB) Number:
276417Study/Protocol ID:
AALL1122Study Phase:
IIPatient Age Group:
ChildrenPrincipal Investigator:
Karol H Kerr, MDClinicalTrials.Gov ID:
NCT01460160For more information about this trial go to ClinicalTrials.Gov
Who can I contact for more information?
Name: Beatriz Kovar
Phone: 315-464-7232
Email: kovarb@upstate.edu